We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HIG:NYSEThe Hartford Insurance Group, Inc. Analysis

Data as of 2026-03-10 - not real-time

$137.95

Latest Price

3/10Risk

Risk Level: Low

Executive Summary

The Hartford (HIG) trades around $138, well below its DCF‑derived fair value of roughly $384, indicating a **substantial undervaluation** of over 170%. Its trailing P/E of 10.3 is markedly lower than the industry average of 17.4, and the forward P/E of 9.5 reinforces the value case. Operating margins remain solid at 20% with an ROE of 21.6%, while a modest payout ratio of 16% and a 1.74% dividend yield suggest the dividend is **highly sustainable** given robust free cash flow of $5.8 bn. Technicals show a bullish trend direction, price sitting above the 50‑day SMA and near the identified support at $136, though the MACD is currently bearish, implying short‑term caution. Analyst consensus is a “Buy” with a median price target of $150, offering an upside of about 9% from current levels, and the market sentiment index is in “Extreme Greed” territory, supporting a contrarian entry.
Overall, the combination of deep valuation discount, strong profitability, low beta (0.52) and stable volume makes HIG an attractive **blend** of growth and value, suitable for investors seeking a defensive play with upside potential. The modest volatility (≈18% 30‑day) and low liquidity risk further enhance its appeal across short, medium, and long horizons.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price near technical support at $136
  • Significant valuation gap to DCF fair value
  • Stable dividend with low payout ratio

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Analyst consensus buy and median target $150
  • Strong operating cash flow and ROE
  • Low beta indicating defensive characteristics

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Sustained premium growth and underwriting margin stability
  • Long‑term upside potential from undervaluation
  • Resilient dividend policy and solid balance sheet

Key Metrics & Analysis

Financial Health

Revenue Growth6.70%
Profit Margin13.52%
P/E Ratio10.3
ROE21.66%
ROA3.72%
Debt/Equity23.94
P/B Ratio2.0
Op. Cash Flow$5.9B
Free Cash Flow$5.8B
Industry P/E17.4

Technical Analysis

TrendBullish
RSI44.8
Support$136.06
Resistance$143.98
MA 20$140.97
MA 50$137.44
MA 200$131.34
MACDBearish
VolumeStable
Fear & Greed Index76.93

Valuation

Fair Value$383.92
Target Price$150.85
Upside/Downside9.35%
GradeUndervalued
TypeBlend
Dividend Yield1.74%

Risk Assessment

Beta0.52
Volatility17.83%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.